Cellebrite to reincorporate in the U.S.
The $2.8 billion digital intelligence company says the move will strengthen its position in the U.S., its largest geographic market, and broaden its investor base, while its Israeli operations are expected to continue as usual.
Less than two years after the departure of Israeli CEO Yossi Carmil, Cellebrite is moving toward relocating its legal domicile to the United States and delisting from Israel. The company announced on Monday that its board of directors has authorized it to pursue a corporate reorganization under which a new U.S. corporation would become the ultimate parent company, subject to shareholder and regulatory approvals.
Moving a company’s place of incorporation from one country to another is relatively unusual for a mature company and can involve the transfer of intellectual property (IP) and other assets. Sources close to Cellebrite said the company’s operations in Israel will continue as usual and that no layoffs are expected.
Cellebrite anticipates completing the reincorporation during the first half of 2027, pending successful shareholder and regulatory approvals. The company said it plans to provide additional details in the coming months, including information related to a special general meeting of shareholders, through additional filings with the U.S. Securities and Exchange Commission.
The company, which trades on the Nasdaq in New York, has a market capitalization of approximately $2.8 billion.
The move is particularly notable given Carmil’s views on the relocation of Israeli technology companies. Carmil, who left Cellebrite after two decades at the company, including most of that time as CEO, said in his farewell interview that “relocation is the greatest threat to Israeli high-tech.” Cellebrite is now taking steps to move its legal incorporation out of Israel.
Cellebrite develops AI-powered digital investigation and intelligence solutions for public- and private-sector customers. Its technology has also been at the center of civil-rights controversies, with its software reportedly used to access or monitor the phones of journalists, public figures and activists.
The company said the U.S. reincorporation is intended to strengthen its position in its largest geographic market and with major government customers outside the United States. The move is also intended to broaden Cellebrite’s investor base through inclusion in key indices.
Shiv Ramji, Cellebrite’s CEO, said, “Redomiciling is a strategic evolution of our company structure. We believe redomiciling in the U.S. will better position us to drive growth across our key customer segments in our largest geographic market as well as with other large government customers outside of the U.S. Redomiciling will also increase Cellebrite's appeal across a broader investor pool through inclusion in key indices.”
